Factset: FactSet Research Systems Inc.2019. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. View which stocks are hot on social media with MarketBeat's trending stocks report.Identify stocks that meet your criteria using seven unique stock screeners. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time.
Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.Get daily stock ideas top-performing Wall Street analysts.
TXMD stock was sold by a variety of institutional investors in the last quarter, including US Bancorp DE, Sanders Morris Harris LLC, and Commonwealth Equity Services LLC.
The company can be reached via phone at 561-961-1900 or via email at Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. 7 analysts have issued 1-year price targets for TherapeuticsMD's stock. See what's happening in the market right now with MarketBeat's real-time news feed. Learn everything you need to know about successful options trading with this three-part video course.Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:You have already added five stocks to your watchlist. Their forecasts range from $1.20 to $15.00. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.02.
High institutional ownership can be a signal of strong market trust in this company.Earnings for TherapeuticsMD are expected to grow in the coming year, from ($0.60) to ($0.26) per share.The P/E ratio of TherapeuticsMD is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.The P/E ratio of TherapeuticsMD is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.TherapeuticsMD has a P/B Ratio of 51.67. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist.
Learn everything you need to know about successful options trading with this three-part video course.Looking for new stock ideas? © 2020 Market data provided is at least 10-minutes delayed and hosted by Learn about financial terms, types of investments, trading strategies and more.MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. All rights reserved.
TherapeuticsMD is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. This suggests a possible upside of 395.6% from the stock's current price.
Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Get short term trading ideas from the MarketBeat Idea Engine. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-00THR and TX-0008HR, which are transdermal patch product candidates. TherapeuticsMD Inc. analyst estimates by MarketWatch. 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. TXMD stock was bought by a variety of institutional investors in the last quarter, including MCF Advisors LLC, Raymond James Financial Services Advisors Inc., SG Americas Securities LLC, Swiss National Bank, Principal Financial Group Inc., Virtu Financial LLC, UBS Group AG, and California Public Employees Retirement System. TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. Top institutional investors include Sanders Morris Harris LLC (1.37%), Swiss National Bank (0.21%), California Public Employees Retirement System (0.19%), SG Americas Securities LLC (0.15%), MCF Advisors LLC (0.15%) and Raymond James Financial Services Advisors Inc. (0.15%).
TherapeuticsMD employs 348 workers across the globe.TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View which stocks have been most impacted by … © American Consumer News, LLC dba MarketBeat® 2010-2020. On average, they expect TherapeuticsMD's stock price to reach $7.53 in the next twelve months. Shares of TXMD can be purchased through any online brokerage account. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. All rights reserved. TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -13.33% and -10.30%, respectively, for the quarter ended June 2020. The average price target is $5.40 with a high forecast of $10.00 and a low forecast of $1.20. Disclaimer. The average price target represents a 223.35% increase from the last price of … Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC.